Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III Data
April 4, 2016 6:21 AM EDT
Leerink Partners analyst Geoffrey Porges reiterated an Outperform rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $523.00 (from $505.00) after dupilumab was substantially de-risked for the atopic dermatitis (AD) indication, and, they believe, for other indications as well (for safety).
"Our... More
April 1, 2016 10:55 AM EDT
Roth Capital analyst Joseph Pantginis trimmed his price target on Regeneron Pharma (NASDAQ: REGN) to $520.00 (from $555.00) but maintained a Buy rating after Dupilumab (Breakthrough Designation) delivered two positive Phase III studies in moderate-to-severe atopic dermatitis.
"The BLA filing is expected in 3Q16 and... More
April 1, 2016 9:25 AM EDT
BlackBerry (NASDAQ: BBRY) 9.2% LOWER; reported Q4 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $464 million versus the consensus estimate of $563.18 million.
Cardiovascular Systems, Inc. (NASDAQ:... More
April 1, 2016 6:57 AM EDT
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Sanofi (NYSE: SNY) announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD) met their primary endpoints. In the studies, known as LIBERTY AD SOLO 1 and SOLO 2, treatment with dupilumab as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, quality of life, and mental health.
"These are the first Phase 3 studies of a systemic therapy to demonstrate a significant improvement in moderate-to-severe atopic dermatitis, a chronic, debilitating inflammatory... More
